



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	27904	CHLORQUIN chloroquine phosphate 250mg tablet bottle
ARTG entry for	Medicine Registered	
Sponsor	Aspen Pharmacare Australia Pty Ltd	
Postal Address	34-36 Chandos Street, ST LEONARDS, NSW, 2065 Australia	
ARTG Start Date	21/10/1991	
Product Category	Medicine	
Status	Active	
Approval Area	Drug Safety Evaluation Branch	

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1 . Chlorquin 250 mg Tablets bottle

Product Type	Single Medicine Product	Effective Date	3/07/2002
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Suppression and treatment of malaria; amoebic hepatitis; in certain phases of lupus erythematosus, rheumatoid arthritis and related collagen diseases. The use of chloroquine is contraindicated - in patients with known hypersensitivity to 4-aminoquinoline compounds -in patients with retinal or visual field changes. In case of an acute attack of malaria, the physician may elect to use this drug after carefully weighing the possible benefits and risks for the patient.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	HDPE	3 Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
bulk tablets	(S4) Prescription Only Medicine
100	(S4) Prescription Only Medicine

Components

1 . Medicine Component

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	Round, flat, white tablet with breakline on one side

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Active Ingredients

chloroquine phosphate 250 mg

Other Ingredients (Excipients)

magnesium stearate

povidone

Starch

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary